Bausch & Lomb vs Edwards Lifesciences
Edwards Lifesciences is the larger business, with $6.07bn of revenue in fiscal 2025 against $5.10bn for Bausch & Lomb (1.2 times as much). Edwards Lifesciences grew faster (11.5% against 6.5%). Edwards Lifesciences kept more of each dollar of sales as profit: a net margin of 17.7% against -7.1%.
| Latest fiscal year | Bausch & LombBLCO, 2025 | Edwards LifesciencesEW, 2025 |
|---|---|---|
| Revenue | $5.10bn | $6.07bn |
| Revenue growth | 6.5% | 11.5% |
| Net income | −$360m | $1.07bn |
| Operating margin | 2.2% | — |
| Net margin | -7.1% | 17.7% |
| Return on equity | -5.6% | 10.6% |
| Free cash flow | −$66.0m | $1.33bn |
| Cash | $383m | $2.94bn |
| Total debt | $5.11bn | $598m |
| Debt to equity | 79.2% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | $893m |
| Employees | — | 16,000 |
| Market value | $7.14bn | $55.12bn |
| Price vs our value range | — | Above our value range |
| Moat score | 19 (Weak) | 96 (Strong) |
| Insider trades, 12 months | 9 buys, 4 sales | 0 buys, 54 sales |